have failed to demonstrate a survival benefit in favour of D2 dissection (Bonenkamp et al, 1999; Cuschieri et al, 1999) , but there is still uncertainty because of strong criticisms of these trials (Brennan, 1999; Roukos, 2000b) .
The assessment of the gastric cancer recurrence risk and outcome is an important and urgent issue, however, cancer and especially gastric cancer is complicated by the fact that recurrence occurs in a variety of forms and in different organs following R0 resection; loco-regional, peritoneal, lymph nodal, haematogenous and combinations of these, constitute the major sites of recurrence. Therefore, the establishment of an extensive Japanese-style surgery for the control of the disease in Western patients is of practical relevance and of even greater social significance because no adjuvant treatment, that would contribute to survival improvement, has yet been established to be effective (Hermans et al, 1993; Roukos, 2000a) . The target of this prospective study, was to assess the effectiveness of a standardized extensive surgery, by evaluating risk factors for recurrence and the overall survival of patients who had previously undergone this surgical approach at a median follow-up of 92 months.
PATIENTS AND METHODS
All consecutive patients with a histologically confirmed gastric carcinoma who had undergone resection between January 1986 and December 1992 were included in this prospective study. We excluded patients who had a palliative surgical procedure without gastrectomy because resection is necessary for accurate histological diagnosis and staging. Patients were also excluded if they had a previous or coexisting cancer.
After surgery, the patients underwent a clinical examination, laboratory tests, X-rays, endoscopic or radiologic examination and abdominal ultrasound every 3 months or computer tomography every 6 months in the first 2 years. Thereafter, all these examinations were performed every 6 months.
Surgery
The guidelines of the Japanese Research Society for Gastric Carcinoma (JRSGC), for the standardization of surgical treatment and pathological evaluation (Nishi et al, 1995) , as well as the recommendations by the American Joint Committee on Cancer (AJCC) and the UICC in the fourth edition of their manual for the staging of cancer (Beahrs et al, 1992) , formed the basis of our protocol. Total gastrectomy with an extended lymph-node dissection was the treatment of choice. A subtotal gastrectomy (SG) was only performed in patients with an early stage (T1) intestinal-type growth pattern, according to the Lauren classification, or in older patients not in good physical condition. Extended (D2) lymph node dissection was performed using a systematic and standardized technique according to the guidelines of the JRSGC. D2 node dissection in our study entailed the removal of perigastric compartment I nodes (stations 1 to 6, attached to the stomach: D1 dissection) and the extraperigastric compartment II nodes (stations 7 to 12) using a technique previously described (Roukos et al, 1998) . The total gastrectomy specimen with greater and lesser omenta and containing nodal stations 1 through 6, including the nodes along the left gastric artery (station 7) was removed enblock and sent to the pathologist. However, the fatty connective tissue containing nodes from each of the 3 major compartment II nodal areas, i.e., hepatoduodenal ligament (station 12), superior border of the pancreas (stations 8, 9 and 11), and spleen hilus (station 10), was separately dissected, labeled and sent to the pathologist. Resection of the spleen was optional.
Pathology and quality control
All histopathological data were prospectively documented in a standardized protocol. The pathological lymph node grouping (pN) was done according to the rules of the JRSGC slightly modified in our protocol pN1 stage: detection of metastasis by pathologist in compartment I lymph nodes (stations 1 through 6), but no metastases in compartment II; pN2: metastases in compartment II nodes (stations 7 through 12) but no metastases in compartment III. For tumour invasion (pT), distant metastases (pM) and curability of resection, the recommendations of the AJCC/UICC were applied.
Obviously, the risk of recurrence should only be studied among patients who had a complete resection in the apparent absence of remaining disease. Because the curability of resection includes, besides the resection of the primary tumour, the dissection of metastatic nodes, we evaluated the risk of relapse among patients who had an extended (D2) node dissection, which ensures an accurate nodal staging. An objective estimation of the risk of relapse among patients who had undergone a limited (D1) dissection appears to be unreliable because a substantial proportion of these patients have remaining disease after a D1 dissection. This because it has been shown that compartment II nodes that are left behind after a D1 resection, are tumour positive in 30% of patients who had a D2 resection with curative intent (Bunt et al, 1995; Roukos, 2000a Roukos, , 2000b .
We used the pathological and surgical findings documented in the protocol to stratify patients according to the curability of resection (curative (R0) or noncurative (R1, R2)) and extent of lymphnode dissection (D1 or D2) based on standardized criteria. Patients were classified as having a curative resection if, at laparotomy, there was no macroscopic evidence of hepatic or peritoneal spread of the tumour or metastatic deposits beyond the compartment II nodes, that the resection resulted in complete macroscopic tumour removal and in the final pathological examination there was no microscopic evidence of tumour cells in all resection lines. The patients who met these macroscopic and microscopic criteria constituted the group treated curatively (R0 resection), all the others who did not meet these criteria constituted the group treated with a palliative intent (R1, R2 resection).
To control the surgical report as to whether a D2 node dissection was completely performed, we used the pathology report from the lymph-node examination. For the quality control, the number of retrieved lymph-nodes per station by the pathologist and the intrinsic biological variation of nodes per station (Marujama et al, 1987) were considered. Details for this quality control are described in an our recent report (Roukos et al, 2000) .
It should be noted that none of the patients treated curatively underwent adjuvant chemotherapy or radiotherapy and thus the surgery alone is responsible for the reported results.
Statistical analysis
All diagnostic, surgical and histopathological data and records of events (death, recurrence or censored patients) were prospectively documented on a standardized protocol. The primary endpoints were recurrence-free survival and overall survival, as measured from the date of surgery to the time of the last follow-up visit or death, irrespective of cause. The treatment effect was primarily evaluated according to the intention-to-treat principle and all the patients were included in the overall survival analysis, irrespective of whether they had an R0 or R1, R2 resection. Because the survival of patients who had noncurative surgery is extremely poor and cannot be affected by any type of surgical or adjuvant treatment, all subsequent analyses were focused on the patients who had undergone an R0 resection. Only the patients who had not died in the hospital after a D2 curative resection were at risk of recurrence, we therefore only estimated the risk of recurrence amongst these patients.
We constructed Kaplan-Meier life-table curves in order to estimate the probability of treatment failure for the endpoints of disease-free survival and overall survival (Kaplan and Meier, 1958) , and used the log-rank test for comparison. Data on patients who were alive and had no evidence of disease at the end of our study or at the last follow-up visit were censored. We used a multivariate Cox proportional-hazards analysis to estimate the prognostic effect of various variables with respect to relapse-free survival and overall survival (Cox, 1972) . A P value of less than 0.05 was considered to indicate statistical difference. For statistical analyses, we used SPSS software for Windows (version 9.0.1).
RESULTS
Of the 210 patients with gastric carcinoma who underwent gastrectomy, 59 (28%) had a non-curative resection and 151 (72%) underwent a curative resection. Of these 151 R0 patients, our criteria for a D2 node dissection were fulfilled by the 124 patients (79%).
Long-term survival for all resected patients
All resected patients were included in the primary analysis of overall survival according to the intention-to-treat principle, irrespective of curability (R0, R1/R2 resection). Of 210 resected patients, 202 (96%) could be followed. During a median follow-up of 54 months, 139 patients died and 63 were alive without evidence of recurrence (31.2%). The curability of resection (curative vs. noncurative, P < 0.001, Figure 1 ), nodal status (pN-stage, P < 0.0001), tumour invasion (pT-stage, P < 0.0001) and extent of surgery (extended vs. limited lymph-node dissection, P < 0.0001) were all significant prognostic factors according to the log-rank test in univariate analysis. In a step-down multivariate analysis, the nodal status (P < 0.0001) and the curability of resection (P = 0.0001) were found to be the strongest significant and independent predictors of outcome.
Further analysis of the results according to the curability of resection shows that the median survival time following noncurative resection was very poor (8 months). The relative risk of death among palliatively resected patients, as compared with those who had a curative resection, was 2.32 (95% confidence interval, 1.53 to 3.52). Since the prognosis of patients with residual disease after resection was extremely poor, and that this dismal survival unfortunately cannot be improved by any type of surgery, we estimated the effect of extensive surgery on loco-regional or any type of recurrence and survival on patients who had a D2 resection with curative potential. Table 1 shows the clinical and tumour characteristics. Most of patients (91%) had a total gastrectomy and an advanced pathological T3-cancer (53%). Of the 124 patients who fulfilled our criteria for a D2 resection with curative intent, there were only 2 postoperative in-hospital deaths (1.6%). One patient was lost to follow-up (0.8%). Of the 121 patients who left the hospital and thus were at risk of relapse, during a median follow-up of 92 months for survivors, gastric cancer recurred in 59 patients (49%). The median time from surgery to the evidence of recurrence or death from gastric cancer for these 59 patients was 10 months (73% recurred within the first two years and only 5% after the fifth year; mean survival time 17.24 months (range 1 to 70). These 59 patients died shortly after the first evidence of recurrence (median time, 5 months (range 0 to 33)). Table 2 shows the sites of first recurrence and status of patients at their last follow-up according to the serosa and lymph node state. The frequency of any type of recurrence increased with serosa invasion and the presence of lymph-node metastases. There was no difference between the intestinal-type and diffuse-type cancer according to the Lauren-classification in any type of recurrence. Evidence of the first site of relapse was obtainable in 34 patients (58%), whereas it was impossible in the remaining 25 patients because of the rapid progression of the disease from surgery to death with multiple metastases in different organs. Among these 34 patients, loco-regional recurrence as the only cause of a first relapse, was rarely assessed (12%), whereas peritoneal or haematogenous recurrences were more frequently evident (88%). Peritoneal dissemination as the only site of recurrence was the most frequent treatment failure (29%).
Survival of patients who had a D2 curative lymph-node dissection
There was a strong correlation between serosa state and the type of recurrence. Peritoneal recurrence occurred exclusively among patients with serosa invasion, whereas none of the serosa-negative cancers had a peritoneal relapse. This figure persisted even though we calculated all patients who had peritoneal failure alone or in combination with other organ recurrences. Of the 20 patients with peritoneal recurrence alone or in combination with other organs, 19 had a serosa invasion (95%) and only one (5%) had a serosanegative cancer (pT2 tumour). Interestingly, in 88% of the patients, the evidence of first recurrence was exclusively confined to the abdominal cavity. However, 29% of these patients had multiple recurrences in different organs (peritoneal surface, liver, local) (Table 2) . Both the lymph-node status (pN category) and tumour invasion (pT category) were found to be significant factors in the prediction of both relapse-free survival and overall survival, whereas the location of the tumour and the Lauren classification had no prognostic relevance in univariate analysis (Table 3) . In a Cox multivariate regression analysis, nodal status and tumour invasion were each found to be significant and independent predictors of both recurrence and gastric cancer-related death (P = 0.002 and P = 0.005, respectively), and of death of any cause (P = 0.002 and P = 0.02 respectively) ( Table 4) .
Pathological serosa and node state-based risk-prediction analysis
Since microscopic nodal and wall invasion (pN, pT categories) were found to be independent predictors of survival and that there was a strong correlation between the serosa status and site of first recurrence, we performed a recurrence and death riskprediction analysis with a combination of both prognostic variables to assess whether this combination could more accurately predict both the risk of relapse and death from any cause. From the stratification of the patients according to both serosa and nodal state derived 4 groups: serosa-, and node-negative cancers (pT 1, 2 N 0 , first group), serosa-positive but node-negative cancer (pT 3 N 0 , group B1), serosa-negative but node-positive cancer (pT 1, 2 N 1, 2 , group B2) and serosa-and node-positive cancers (pT 3 N 1,2 , third group). It was found that there was no significant difference between the patients in groups B1 and B2 with respect to either relapse-free survival (P = 0.72) or overall survival (P = 0.38) and thus these 2 subgroups were included in the same group (second group; pT 3 N 0 , pT 1, 2 N 1,2 ).
Of 47 patients in the third group, 39 recurred and died (83%), whereas of 32 in the second group, 16 recurred and died (50%). Among 42 patients in the first group only 4 recurred and died (10%) ( Table 2 ). As shown in Figure 2 , after 10 years of followup, patients in the first group were at low risk (11%), those of second group at high risk (53%) and those of the third group at very high risk (83%) of recurrence and death from gastric cancer. The differences between the 3 groups in both risk of recurrence and death from gastric cancer or death from any cause were, by log-rank test, highly significant (P < 0.0001).
We performed a Cox multiple-regression analysis, entering these 3 groups into the model (Table 5 ). This classification accurately predicted both the cumulative risks of recurrence and death from gastric cancer and of death from any cause. The relative risks of recurrence and death from gastric cancer among patients in the second and third groups, as compared to that in first group, were 7.07 (95% confidence interval (CI, 2.36-21.17; P = 0.0005) and 16.19 (95% CI, 5.76-45.54; P < 0.0001) respectively).
DISCUSSION
Our results confirm that curative resection (R0) is a very strong and independent predictor of outcome for gastric cancer. The survival for all other patients with remaining disese after resection is extremely poor and cannot be improved by any type of treatment, thus our study focused on patients who had an R0 resection. Although surgery with curative potential is without doubt the treatment of choice, controversy still remains as to the optimal extent of this resection. The hypothesis for the improvement of both local control and survival and the favourable findings with respect to an extended lymph node dissection in reports from East (Marujama et al, 1987; Fujii et al, 1999; Kim, 1999) , and West (Siewert et al, 1998) , have not been confirmed by 2 recent European randomized trials (Bonenkamp et al, 1999; Cuschieri et al 1999) . Controlled trials are the best method for making treatment decisions (Sackett et al, 1996) , but criticism regarding their appropriateness of design and conduct (Brennan, 1999; Roukos, 2000b) . Have lead now to an uncertainty over the optimal extent of surgery. We conducted this study in order to assess the potential of a Japanese-type radical surgery in Western patients. Because experience and pancreas preservation are predominant factors for both the safety and completeness of an extended lymph node dissection (Siewert et al, 1998; Brennan, 1999; Roukos, 2000b) , we started this study after gaining 7 years experience with D2 dissection (Roukos et al, 1990) . This strategy and the low rate of pancreatectomies explains the low rate of in-hospital mortality (1.6%) in our study, which is similar to that of other reports (Marujama et al, 1987; Siewert et al, 1998; Fujii et al, 1999; Kim, 1999) suggesting the safety of the D2 procedure when the criteria of a surgeon's experience and pancreas-preserving technique are met. The low rate of in-hospital mortality with a high rate of prospective The tumour-node-metastasis classification of the Union International contre le Cancer (UICC) and the American Joint Committee on Cancer, 4th edition was used. This analysis included all 123 patients who were at risk of death due to any cause including the 2 in-hospital deaths.
c The log-rank test was used. documentation of all events, allows a follow-up in nearly all of the patients enrolled in the study.
UICC/AICC classification predicts accurately overall survival but is not able to predict overall recurrence and site-specific recurrencerisks. A recurrence-risk prediction analysis on patients who had an R0 resection is important in determining both the potential and limitations of surgery and therefore in making decisions about the need for adjuvant treatment. Our study confirms the predictive value of tumour depth (pT-category) and nodal status (pN-category); however, both a pathological serosa and node state-based classification of patients into 3 major subgroups proved to be of clinical significance for 3 reasons.
Firstly, this classification was highly accurate in predicting recurrence-risk and death among patients who had either both serosa and node negative cancer (first group, low risk; 11%) or both positive (third group, very high risk; 83%). The difference in the risk of treatment failure between these two groups was highly significant in multivariate analysis (relative risk 16.19, 95% CI 5.76-45.54; p < 0.0001). However, in the second group of patients with either serosa-or node-positive cancer, this predictive value was not high (53%).
Secondly, a serosa and node state-based classification proved useful in predicting the site of first recurrence-risk. Obtaining This analysis included all 121 patients who were at risk of relapse; 2 in-hospital deaths were excluded. All 59 patients who relapsed died shortly after the evidence of recurrence (median time, 5 months).
c This analysis included all 123 patients who were at risk of death of any cause including the 2 in-hospital deaths. Pathological tumour stage (pT) according to UICC/AJCC system. 6 The abbreviation CI denotes the confidence interval. Patients were stratified according to the pathological evidence of serosa invasion (pT3) or not (pT1, pT2) and the presence of lymph-node metastases (pN1, pN2) or not (pN0). Pathological tumour staging was done according to UICC/AJCC system, 4th edition, 6 and nodal staging (pN) according to JRSGC.
c
This analysis included all 121 patients who were at risk of relapse; the 2 in-hospital deaths were excluded. All of the 59 patients who relapsed died shortly after the evidence of recurrence (median time, 5 months). Figure 2 Kaplan-Meier relapse-free survival curves for patients with gastric cancer, stratified according to both the pathological serosa-and node-state based classification. The differences in the cumulative risks of recurrence and death from gastric cancer between the 3 groups of patients with both serosa-and node-negative cancer (first group; pT 1,2 N 0 ) or either serosa-or node-positive cancer (second group; pT 3 N 0 , pT 1,2 , N 1,2 ) or both positive cancer (third group; pT 3 N 1,2 ) were highly significant (P < 0.0001)
